Effects of Pitavastatin on Lipoprotein Subfractions and Oxidized Low-density Lipoprotein in Patients with Atherosclerosi
- PDF / 434,621 Bytes
- 6 Pages / 595.276 x 841.89 pts (A4) Page_size
- 47 Downloads / 218 Views
40(5):879-884,2020
879
Effects of Pitavastatin on Lipoprotein Subfractions and Oxidized Low-density Lipoprotein in Patients with Atherosclerosis* Rui-xia XU†, Yan ZHANG†, Yue ZHANG, Ya-ru WU, Xiao-lin LI, Yuan-lin GUO, Geng LIU, Qian DONG, Jian-jun LI# State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China Huazhong University of Science and Technology 2020
Summary: It has been demonstrated that pitavastatin can significantly reduce low-density lipoprotein (LDL) cholesterol (LDL-C), but its impact on lipoprotein subfractions and oxidized low-density lipoprotein (oxLDL) has not been determined. The aim of the present study was to investigate the potential effects of pitavastatin on subfractions of LDL and high-density lipoprotein (HDL) as well as oxLDL in untreated patients with coronary atherosclerosis (AS). Thirty-six subjects were enrolled in this study. Of them, 18 patients with AS were administered pitavastatin 2 mg/day for 8 weeks and 18 healthy subjects without therapy served as controls. The plasma lipid profile, lipoprotein subfractions and circulating oxLDL were determined at baseline and 8 weeks respectively. The results showed that pitavastatin treatment indeed not only decreased LDL-C, total cholesterol (TC), triglycerides (TG) and apolipoprotein B (ApoB) levels, and increased HDL cholesterol (HDL-C), but also reduced the cholesterol concentration of all of the LDL subfractions and the percentage of intermediate and small LDL subfractions. Meanwhile, pitavastatin could decrease plasma oxLDL levels. Furthermore, a more close correlation was found between oxLDL and LDL-C as well as LDL subfractions after pitavastatin treatment. We concluded that a moderate dose of pitavastatin therapy not only decreases LDL-C and oxLDL concentrations but also improves LDL subfractions in patients with AS. Key words: pitavastatin; atherosclerosis; lipoprotein subfraction; low-density lipoprotein
Dyslipidemia, mainly presented as increased lowdensity lipoprotein cholesterol (LDL-C), is a very common disorder and has been proven to be closely associated with the development and progress of atherosclerotic cardiovascular disease (ASCVD)[1]. Moreover, a large number of studies have indicated that elevated LDL-C concentration accompanied by lower high-density lipoprotein cholesterol (HDL-C) levels could aggravate the diseased process of ASCVD, resulting in cardiovascular events (CVEs)[2]. However, the use of biomarkers alone such as LDL-C or HDL-C did not provide adequate information regarding the disease development or future events. Rui-xia XU, E-mail: [email protected]; Yan ZHANG, E-mail: [email protected] † Both authors contributed equally to this study. # Corresponding author, E-mail: [email protected] * This work was supported, in part, by Capital Special Foundation of Clinical Application Research (No. Z121107001012015), Capital Health Development Fund (No. 201614035), C
Data Loading...
